<DOC>
	<DOCNO>NCT02942693</DOCNO>
	<brief_summary>It randomize phase II study determine efficacy safety particle therapy without apatinib induction therapy treatment head neck adenoid cystic carcinoma . Participants randomize arm 1 : receiving apatinib 6 weekly follow particle radiotherapy ; arm 2 : particle radiotherapy alone .</brief_summary>
	<brief_title>Trail Evaluating Particle Therapy With Without Apatinib H &amp; N Adenoid Cystic Carcinoma</brief_title>
	<detailed_description>The purpose study determine efficacy safety particle therapy without apatinib induction therapy treatment head neck adenoid cystic carcinoma . It randomize phase II clinical trial single phase 2 experimental arm . Participants randomize arm 1 , receive apatinib ( 0.5g , daily ) 6 weekly follow particle radiotherapy ( proton : 56 GyE/28 Fx , plus carbon : 15 GyE/5 Fx boost ) ; arm 2 : particle radiotherapy alone ( proton : 56 GyE/28 Fx , plus carbon : 15 GyE/5 Fx boost ) . The short term response evaluate use RECIST criterion . And acute late toxicity evaluate accord NCI CTCAE v4.03 .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Adenoid Cystic</mesh_term>
	<criteria>Pathologically confirm ACC Inoperable disease postoperative residual disease detect image study Age ≥ 18 ≤ 65 year age ECOG &lt; 2 , significant active concurrent medical illness Adequate laboratory value within 30 dyas enrollment study define follow : N &gt; 2000/mm^3 ; PLT &gt; 100,000/mm^3 ; total bilirubin &lt; 1.5mg/dl ; AST/ALT &lt; 1.5 ULN ; SCr &lt; 1.5mg/dl ; CCR &gt; 60ml/min Willing accept adequate contraception woman childbearing potential Ability understand character individual consequence clinical trial Willing sign write informed consent ; Informed consent must sign enrollment trial Presence distant metastasis Pregnant lactate woman A diagnosis malignancy CIS cervix , BCC SCC skin within past 5 year Refusal patient participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Apatinib</keyword>
	<keyword>Particle therapy</keyword>
</DOC>